WeedLife News Network

Hot off the press cannabis, marijuana, cbd and hemp news from around the world on the WeedLife News Network.

Waretown To Update Cannabis Ordinance

The Township of Ocean’s governing body is further weeding through the details in making changes to its cannabis business ordinance.

The first reading of the proposed amendments and supplements to the ordinance passed unanimously at this month’s committee meeting. Residents will have the opportunity to discuss the changes at the second reading of the ordinance at the August 2 Township Committee meeting.

“The Township of Ocean is now putting in place the criteria for cannabis in the Township of Ocean,” said Mayor Ben LoParo, adding that the governing body will review it before the vote in a public meeting. “The applicant will need to provide the ownership of the business, business plan, and community benefits.” The proposed ordinance requires applicants to pay a $2,500 non-refundable application fee. Additionally, the Township of Ocean plans to collect a $10,000 annual fee for businesses that operate cultivation, manufacturing or medical cannabis facilities in the municipality.

Four types of licenses will be available withing the municipality if the ordinance is approved. A Class 1 License is for Cannabis Cultivation; Class 2, Cannabis Manufacturing, Class 3, Cannabis Wholesale; and Class 4, Cannabis Distribution. A separate license covers medical dispensaries. LoParo pointed out that the ordinance excludes the retail sale of recreational marijuana even though 57 percent of the municipality’s voters were in favor of the legalization of adult recreational cannabis use.

“I don’t think that’s right,” said LoParo. “I think we should include it because our voters said yes. We’re doing our people a disservice by not giving them what they voted for…We’re also giving up two percent of the recreational income, which could wind up to be hundreds of thousands of dollars in our tax account.”

LoParo pressed for feedback from the two other members of the township committee. Deputy Mayor Ken Baulderstone said he first wanted to see how the medical dispensary “worked out” before considering recreational retail sales. “The steps that we have taken are already more than eighty percent of the municipalities in the state,” Baulderstone stated.

e-mail icon
Continue reading

Where Cannabis Legalization efforts stand across the Country

Gains in state legislatures slowed down in 2022, but advocates still have the ballot. State lawmakers are still wary of weed.

Last year, four states legalized marijuana through their legislatures. So far in 2022, only one — Rhode Island — has managed to legalize recreational marijuana, even though public support for liberalizing cannabis laws remains at an all-time high.

With most legislative sessions across the country already wrapped up for the year, the results are clear: “Elected officials remain far behind the times,” said Karen O’Keefe, state policy director for Marijuana Policy Project. If it were left up to voters, O’Keefe believes, every state would have some form of legal cannabis by now.

As it stands, 19 states have embraced full legalization, while 19 others have enacted medical marijuana programs. But many of the remaining holdouts are staunchly conservative states where legalization skepticism runs deep among lawmakers.

Perhaps the biggest setback for industry advocates this year was Delaware, where a bill to remove penalties for possession passed with supermajorities in both chambers, only to be vetoed by the Democratic governor, John Carney. Recreational legalization efforts also came up short in Ohio, Hawaii and New Hampshire, while medical bills failed in Kansas, South Carolina, Tennessee and Kentucky.

Some legislative efforts were doomed from the outset, particularly Democratic-sponsored adult-use bills introduced in GOP-dominated state legislatures such as Louisiana, Wisconsin and Indiana.

e-mail icon
Continue reading

Beto O’Rourke Tell Texas Veterans He Wants to Legalize Marijuana

At a series of town halls with Texas Veterans, Beto O’Rourke said he’ll fight to legalize marijuana if elected governor.

While continuing his visits across Texas, at a series of earlier town halls O’Rourke has said he has received positive support from Veterans on the marijuana issue.

O’Rourke tweeted on Wednesday: "Veterans say it’s time for this state to legalize marijuana. The people of Texas agree. Now we just need a governor who will get it done."

In Texas, veterans account for about 157,761 people as of 2019 according to Texas Workforce Investment Council.

As early as March, O’Rourke voiced his support in Austin at a dinner for the South by Southwest panel.

O’Rourke said: “I’ll let you in on a secret: Republicans like to get high just as much as Democrats.”

e-mail icon
Continue reading

Veriheal Reports The Demand for Medical Cannabis Is Skyrocketing

The use of medical cannabis is rapidly rising in the United States. Of the 50 states, 37 have legalized medical marijuana and 19 have legalized recreational use. This has resulted in a total of $3.7 billion in cannabis tax revenue and increasingly widespread awareness of the plant’s pain-relieving qualities and potential to treat other illnesses and conditions.

According to a study published in Annals of Internal Medicine, the number of registered U.S. medical cannabis patients quadrupled between 2016 and 2020 to nearly 3 million total. This supports statistics from cannabis health technology company Veriheal, which reported 170,000 newly enrolled Florida patients in 2020 alone.

Medicinal Marijuana as an Alternative to Pills

The cannabis plant can assist in alleviating various conditions, from insomnia and Crohn’s disease to PTSD and depression. Considering that over 20% of Americans suffer from chronic pain—historically the most common reason people opt for medical cannabis—researchers have homed in on the potential of cannabis as a safer alternative to addictive opioid-based painkilling medications. Opioids have claimed hundreds of thousands of U.S. lives since the 1990s.

A study published in 2015 found that the use of medical cannabis “was associated with improvements in pain, function, quality of life and cognitive function.” The efficacy of cannabis as pain treatment has led to significant decreases in opioid use. According to a study, opioid overdose deaths were reduced by 25% in states that enacted medical cannabis programs.

Millennials were the biggest demographic of medical marijuana cardholders in 2020, followed by Generations X and Z. Statistics indicate that the COVID-19 pandemic combined with heavy political tension in 2020 caused these groups to experience depressive episodes, stress, and anxiety. Instead of seeking out traditional medications that often come with severe side effects, these groups chose cannabis as a tool for improving their mental health.

e-mail icon
Continue reading

Cannabis users less likely to face complications after spinal fusion surgery

Is there a relationship between cannabis use and outcomes in spinal surgery and other procedures?

While there is limited literature examining the potential connection, a team of orthopedic specialists sought further answers. They ultimately found that patients with a history of cannabis use are indeed less likely than non-users to experience adverse medical outcomes after thoracolumbar (lower back) spinal fusion (TLF) surgery. The study, “The Impact of Isolated Baseline Cannabis Use on Outcomes Following Thoracolumbar Spinal Fusion: A Propensity Score-Matched Analysis” was recently published in The Iowa Orthopedic Journal.

The orthopedic specialists, affiliated with the State University of New York (SUNY) Downstate Health Sciences University in Brooklyn, analyzed the relationship between cannabis use and surgical outcomes with a 704-patient cohort, all undergoing TLF surgery for adult spinal deformity (ASD). Researchers queried the New York Statewide Planning and Research Cooperative System database between January 2009 and September 2013 to identify all patients who underwent TLF for ASD. To be included, individuals were over the age of 18 and had either minimum 90-day or two-year follow-up surveillance.

According to the researchers, ASD is a spectrum of disorders presenting in late adolescence or adulthood and includes adult spinal scoliosis, iatrogenic spinal deformity and primary degenerative sagittal imbalance. The authors note that, as life expectancies increase, the prevalence of ASD is rising and more surgical corrections are expected to occur in the future.

“With shifting public sentiment, expanding decriminalization, and a lack of objective data on the potential consequences of cannabis use, it is imperative to identify how baseline cannabis use impacts postoperative outcomes of patients with adult spinal deformity (ASD) undergoing thoracolumbar fusion (TLF),” the study reads.

Half of the sample identified themselves as cannabis consumers and the other half did not. The study looked to compare 90-day complication, 90-day readmission, and two-year revision rates between cannabis users and non-users.

e-mail icon
Continue reading

Curaleaf launches plant precision, new product line targeting specific health and wellness categories

Plant Precision fills consumer demand for low dose THC formats that are geared towards everyday wellness as 75% of Americans would consider using cannabis for health and wellness purposes

Curaleaf Holdings, Inc. (CSE: CURA /OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced the launch of Plant Precision, a curated collection of edibles and a topical gel designed to target specific wellness categories.

According to a Curaleaf / Harris Poll survey, 69% of Americans say they would be more likely to use cannabis as a health solution if it came in small, controlled doses*. Curaleaf recognized this need and created an approachable line for the newer wellness-oriented consumer featuring gummy edibles offering low, customizable doses of THC and high doses of non-psychoactive therapeutic minor cannabinoids like CBD, CBG, CBN and THCV, and a quickly absorbent THC topical gel.

Plant Precision allows consumers to explore a range of potentially therapeutic destinations such as:

Balance: an apple-flavored gummy containing 2.5mg THC and 10mg CBD for waking up, winding down, or providing a moment of calmSlumber: a cherry-flavored gummy containing 2.5mg THC and 10mg CBN which could be a helpful addition to a nighttime routine to help fall (and stay) asleepSoothe: a pineapple-flavored gummy containing 2.5mg THC and 10mg CBG for rebounding after travel, long workouts, or long weekendsBoost: a lemon-flavored gummy containing 2.5mg THC and 10mg THCV for starting your day with a little extra buzzRelieve: a high absorbing topical gel with 100% THC designed to rapidly ease tension with a 30–45-minute onset time

The minor cannabinoids featured in Plant Precision gummies are non-psychoactive and do not create the euphoric feeling like THC does, but instead interact differently with the human receptor systems yielding different biological effects. The Plant Precision gummies utilize liposomal encapsulation, a technology which envelopes the cannabinoid molecules, to help maximize every milligram. Moreover, each of the Plant Precision Gummy lines contain formulated blends of terpenes that contribute to the entourage effect, which occurs when minor cannabinoids interact with THC to create a unique effect with potential therapeutic benefits.

The Plant Precision Topical Gel was engineered using hydro-alcoholic technology to facilitate the delivery of cannabinoids through the skin and contains 650mg of total THC** – higher than nearly all marketed THC topicals.

e-mail icon
Continue reading

The science behind why music sounds so much better when you’re high

 

The altered state of perception you experience when high on marijuana can change the way you perceive your senses, including the way you hear your favorite songs.

Quality weed and a great record could be considered the perfect pairing by many cannabis and music enthusiasts. After all, marijuana has had a long history and close relationship with music.

From clouds of intoxicating smoke rising from crowds at music festivals this summer, to the lyrics in many classic songs, marijuana is present. And while there is no denying this close relationship, you are apt to wonder exactly why music sounds so much better when you’re high.

As we previously reported, scientists have long been interested in how marijuana affects the way we perceive sound. Unfortunately, studies on marijuana and music, and how it affects sound perception in general, remain scarce due to marijuana’s illegal status. Still, there is some information and insight to draw from in order to help understand why marijuana can make a song sound so much better with it than without it.

One study from 1970 showed the ability of marijuana to perceivably span time, “The smoked marijuana altered pulse rate, time estimation, and EEG.” In fact, the perception of 15 seconds of time, according to the study, was “expanded” to 16.7 seconds. This could possibly explain why those under the influence of marijuana have an ability to notice minute details, and pay particular attention to a piece of music. After all, they have more time to do so — theoretically speaking anyway.

In fact, marijuana taps into our minds in all sorts of ways, many of which seem to positively influence how we perceive things, including music. “Marijuana also accesses a special neurotransmitter system, the endocannabinoid system, which regulates appetite, pain, mood and memory. The way the plant activates this system explains a lot of the unique effects it has on music listening,” according to MIC. Some of these influences, like changes in the endocannaboid system, may be imperceptible at the time, but can change the way we feel when we experience sounds.

e-mail icon
Continue reading

Does smoking marijuana increase the risk of lung cancer? The jury’s still out

 

Though marijuana use is now legal in most of the United States, questions remain about how smoking marijuana can affect lung health and the risk of lung cancer in particular.

Research has suggested that smoking marijuana can cause damage to the lungs but is not as detrimental as smoking tobacco.2-4 Studies have also indicated that smoking marijuana may not increase a person’s risk of lung cancer, but robust evidence is lacking.2-9

“We concluded that there is moderate evidence that there is no association between cannabis smoking and lung cancer,” said Donald I. Abrams, MD, professor emeritus of medicine at the University of California San Francisco and integrative oncologist at the USCF Osher Center for Integrative Health. 

Dr Abrams is one of the experts who reviewed evidence on the health effects of cannabis for a report published in 2017 by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Among the research reviewed for that report was a pooled analysis of 6 case-control studies encompassing 2159 individuals with lung cancer and 2985 control participants. The analysis showed “little or no association” between the intensity, duration, cumulative consumption, or age at the start of cannabis smoking and the risk of lung cancer. 

Another study reviewed for the NASEM report was a population-based study of cannabis use in 49,321 Swedish military conscripts. Researchers evaluated the risk of lung cancer over a 40-year follow-up period. They found a 2-fold increase in lung cancer risk among participants with a history of “heavy” cannabis use (defined as having smoked more than 50 times at baseline) compared with those who had no history of cannabis use. 

e-mail icon
Continue reading

A new study conducted on weed vapes suggests they’re inherently harmful to our bodies.

A new study shows further evidence of the harms of vaping.

Conducted by researchers from Portland State University and published in the journal of Chemical Research in Toxicology, the study claims that the process of heating up cannabinoid acetates creates a toxic gas called ketene that’s harmful to the lungs.

Researchers tested different cannabinoid acetates and tried to measure how much ketene was produced in a single vape puff. They measured acetates like delta-8 THC, a compound that’s currently unregulated by the FDA and that’s potent, crossing the blood-brain barrier more easily.

Researchers found that ketene is formed at lower settings of heat than anticipated and that each puff releases an amount of toxin that’s dangerous to people’s health. Ketene is supposedly so toxic to humans that it’s dangerous to even test it, thus, becoming difficult to measure its impact on the human body.

“The thing we’re most concerned about is prolonged exposure, we don’t know what that is,” said Kaelas Munger, a doctoral student and one of the authors of the study.

“That’s why papers like ours are needed. Otherwise people would be exposed to this really toxic substance and it’s really impossible to look for the evidence.”

e-mail icon
Continue reading

Colorado’s MedPharm continues to blaze path for cannabis research in Alzheimer’s patients

MedPharm Research, a leading cannabis researcher, announced today that the company’s proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled “Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease,” has been selected for funding.

Scoring of the proposal was organized into six categories: significance, approach, broader impacts, environment, data analysis, and environment. Reviewers from the ICR review panel applauded the novelty of the project, the training needed for a scientific intern, and how well the proposal defines the metric of evaluation for each data analysis aim. They concluded that the likelihood of the project to succeed is high, adding that minor cannabinoids is an area where more research is needed.

According to the Center for Disease Control, Alzheimer’s disease and related dementias are projected to grow to 13.9 million, nearly 3.3 percent of the population in 2060. Brains of people with Alzheimer’s show neurodegeneration and high levels of oxidative stress and inflammation.

“The study results will allow MedPharm to further develop innovative, bioavailable, and bioequivalent dosage forms. These are important elements in support of Investigational New Drugs (INDs) and New Drug Applications (NDAs) for future FDA-approved products,” says Scott Karolchyk, MS, RPh, Director of Formulation and Development. The phytocannabinoid cannabidiol (CBD) has neuroprotective, antioxidant and anti-inflammatory properties. Other studies have shown that CBD has been shown to be effective in vivo, making the phytocannabinoid an interesting candidate for novel therapeutic interventions in Alzheimer’s therapy, especially because there are no psychoactive or cognition-impairing properties, thus adding to the significance of the MedPharm study.

“It’s by pursuing this one-of-a-kind study in an area where research is really needed that sets MedPharm apart from other cannabis research and development companies,” Albert Gutierrez, President of MedPharm, says.

e-mail icon
Continue reading

WEED Inc. acquires Hempirical Genetics, with over 250 proprietary cannabis & hemp strains for $750K

WEED, Inc. a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases, acquired 100% of Hempirical Genetics, LLC, for 2 million shares of common stock valued at $.25 per share and $250,000 in cash over 4 years. One million shares and $10,000 was paid on signing this agreement. (Benzinga)

Glenn E. Martin, WEED, Inc.'s CEO stated, "Our teams in USA, Australia and Israel are excited that a pipeline of Original "Landrace" strains from the 1970s' can now be moved into clinical trials and product development for the global market. WEED now has over 15 "PURE" original, pristine, F-1 grade cannabis strains today, including, Panama Red, Acapulco Gold, Red Bud Colombian & Santa Marta Gold. Our newly acquired inventory includes over 30 CBD & CBG strains as WEED believes that multiple combinations of precise cannabinoid strains will create the entourage effect to achieve the medical outcome desired. Eventually, WEED plans to bring our unique desired strains to the Adult Use markets once the "Law of the Land" brings back the Freedoms lost 70+ years ago."

Jeffery Miller, the previous owner of Hempirical Genetics, will lead the charge in strain & product development as HEMP BioScience's new CEO. Martin continued, "I've known Jeff for a half a century. His horticulture skills and dedication the Cannabaceae plant cannot be duplicated. I'm extremely proud to have my old friend and his team, (whose strains WEED bought in the acquisition), which we believe will bring year-over-year success to the benefit of WEED's shareholders."

Miller stated, "I've known Glenn Martin for 50+ years and honored to take the helm of HEMP BioSciences to buildout our genetic studies. My goal is to bring the strongest, highest quality THC and hemp products to market at affordable prices.

"Double the quality, half the price" should be the mantra for the cannabis industry, while creating diversity & equality to the cannabis sector. Our Veterans have been highly overlooked, and I look to develop vet programs at low or no cost, which I know is a priority of Glenn and mine."

 

e-mail icon
Continue reading

CBD may be effective for pain management after certain surgeries

A new study says cannabidiol (CBD) can effectively relieve post-operation pain from rotator cuff surgery while being at least as safe as opioids.

The study was presented last weekend at the American Orthopaedic Society of Sports Medicine annual meeting in Colorado Springs.

It detailed research led by Dr. Michael J. Alaia, a sports orthopedic specialist at NYU Langone Health in New York City.

The findings haven’t yet been peer-reviewed or published in a medical journal.

Alaia’s team established a multi-center trial involving 80 subjects from 18 to 75 years of age. One group received a placebo. The other received CBD for 14 days. In the CBD group, the dosage was either 25 mg or 50 mg, depending on the subject’s weight.

The participants’ pain level was recorded on days one two, seven, and 14. Researchers used the visual analog scale (VASTrusted Source) for pain, opioid consumption, and satisfaction with pain control. Liver function was measured on days seven and 14 to assess safety and nausea was monitored.

e-mail icon
Continue reading

Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year

The Cannabis Scientist Power List is an annual recognition of the most important innovators within the cannabis industry

Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today celebrated Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, being named to the Cannabis Scientist Power List for the third consecutive year. Dr. Markus Roggen is consistently recognized as one of the most influential figures in the processing professionals category because of his commitment to creating a body of work on cannabis research that will have a lasting effect on the industry for the better. Under Dr. Roggen's leadership, Delic Labs will transfer their expertise and experience from the cannabis sector to establish itself as the leader in psychedelic research and safety testing. The lab has received Health Canada 56 exemptions for chemistry analytics on psilocybin mushrooms; to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD; and has received psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs expects to receive within the next months a Dealer's License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.

With the Health Canada 56 exemptions and a Dealer's License, the Company plans to implement consistent quality control standards to enhance the use of psychedelic compounds for medical purposes.

Rate this article: 
Select ratingGive Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year 1/5Give Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year 2/5Give Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year 3/5Give Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year 4/5Give Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

Tilray Medical launches cannabis education platform ‘WeCare-MedicalCannabis’ across Europe

WeCare-MedicalCannabis’ A Comprehensive Resource for Medical Cannabis Education is Now Available in English, German, French, and Portuguese

 Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, launched a new cannabis education platform, WeCare-MedicalCannabis, dedicated to providing resources and educating healthcare practitioners and patients about medical cannabis.

WeCare-MedicalCannabis provides science and research-based cannabis content tailored to healthcare professionals, caregivers, and patients to help them make informed decisions about medicinal cannabis and assists them along their path to discovering how medicinal cannabis can support daily wellness and health. Designed to serve as a one-stop, comprehensive resource on medical cannabis insights, WeCare-MedicalCannabis is now available in Germany, France, the United Kingdom, and Portugal.

Sascha Mielcarek, Managing Director, Tilray Europe, said, “As global pioneers in medical cannabis, we are aware of the lack of access to science-based, medical cannabis education. WeCare-MedicalCannabis was created to bridge that gap and help provide the needed resources to helping patients, caregivers, and healthcare professionals with the information they need to make informed decisions on medicinal cannabis. As cannabis legalization continues to expand across Europe, Tilray Medical is dedicated to help provide informed and trusted guidance for those interested in learning more about medical cannabis.”

Tilray Medical continues to work with leading patient associations and physician societies, providing value to those impacted by changes within the medical landscape, and who serve at the forefront of global health initiatives. By providing access to educational platforms such as WeCare-MedicalCannabis, Tilray Medical continues to open and expand its world of wellbeing.

Rate this article: 
Select ratingGive Tilray Medical launches cannabis education platform ‘WeCare-MedicalCannabis’ across Europe 1/5Give Tilray Medical launches cannabis education platform ‘WeCare-MedicalCannabis’ across Europe 2/5Give Tilray Medical launches cannabis education platform ‘WeCare-MedicalCannabis’ across Europe 3/5Give Tilray Medical launches cannabis education platform ‘WeCare-MedicalCannabis’ across Europe 4/5Give Tilray Medical launches cannabis education platform ‘WeCare-MedicalCannabis’ across Europe 5/5
Authored By: 
Regional Marijuana News: 

e-mail icon

Homegrown hemp brands that focus on cannabis for stress, pain and skin relief

Infuse a bit of calm in your mind and body care rituals with the therapeutic effects of cannabis

A green bottle of hemp seed oil proudly sits next to avocado and olive oil on my kitchen shelf. Albeit not daily, it occasionally finds its way into my salads, or on my skin when it’s going through extreme bouts of dryness. Hemp seed oil comes with numerous benefits—filled with fatty acids like Omega 3, 6 and 9, proteins and vitamins—consumed or applied topically. From oils and tinctures to hemp-infused creams and even makeup—the once notorious plant has officially infiltrated Indian households in various forms. Discovered in 1940, cannabidiol, or CBD, is one of more than hundreds of cannabinoids found in cannabis, and unlike its scandalous cousin THC, it is non-psychoactive i.e. it won’t get you high. It will, instead, lend its therapeutic properties against a varied range of conditions. According to a cross-sectional study of cannabidiol users, CBD was used as therapy to particularly combat pain and inflammatory disorders, in addition to anxiety, depression, and sleep disorders. Ahead, we pick the homegrown brands that are harnessing the power of the plant to bring relief to the mind and body.

River Remedy

From a massage oil and eau de parfums to sunscreens and a day cream, River Remedy features lab-tested and certified, pure hemp in all these products, with an overarching goal to release tension and relieve stress. Turn your night routine into a therapeutic ritual by massaging the Dream Cream—a creamy concoction of hemp, shea, macadamia and apricot butters—on the face and behind the ears for a restful and repairative sleep.

Satliva

Satliva sources its hemp seeds from government approved vendors in the Himalayas, extracting its oil and combining it with other cold pressed oils in their product range that includes body butters, soaps, hair oils and more. Each product is also made made to order, to preserve the maximum benefits of their natural ingredients that are devoid of chemicals or preservatives. This means, only when you add it to your cart will the hemp seed oil extraction and activation process for your product begin. Try their Hemp with Jojoba Body Oil for a deeply nourishing and calming experience.

Awshad

From CBD gummies for humans and CBD oil for dogs to full spectrum CBD tinctures coupled with other therapeutic ingredients like tulsi and peppermint, Awshad products offer relief from stress and anxiety, pains and sleep trouble with the healing herb as its hero. They recommend consulting with their in-house doctor to pick the right remedy based on your needs. Try their Premium CBD Gummies to tackle anxiety, insomnia and for an overall state of rest and relaxation.

Boheco

Launched in 2013, Bombay Hemp Company has created a wide range of hemp and medicinal cannabis products including capsules and tinctures that tackle various ailments like neuropathic pain, insomnia, stiff muscles, arthritis, menstrual pain and more. Get their multipurpose raw, unrefined and cold-pressed Hemp Seed Oil as a dressing for your salads and soups, or as an antidote to dry hair, scalp or skin.

e-mail icon
Continue reading

Wellnex Life teams up with OneLife Botanicals to penetrate Australia’s medicinal cannabis market

 

Wellnex Life’s (ASX: WNX) strategy to penetrate the medicinal cannabis and hemp market in Australia is a step closer under a joint venture with Victoria-based producer OneLife Botanicals.

OneLife is a licensed cannabis producer and manufacturer and has what Wellnex describes as a world-class cannabis production, research and development facility.

It is licensed to generate up to 20 tonnes of product a year.

Under the joint venture terms, Wellnex will have the “first right of refusal” on OneLife’s cannabis-based raw materials and products, which will be sold under a jointly developed brand.

Wellnex chief executive officer George Karafotias said the joint venture will enable the company to be one of the first in bringing cannabis-based products to the Australian market.

“We are targeting production of a medicinal cannabis product appropriate for the Special Access Scheme (SAS) market by the end of this year, and are aiming to have a registered product in the Schedule 3 (S3) market by the end of calendar year 2023.”

e-mail icon
Continue reading

NuggMD launches its leading marijuana telemedicine service in Michigan

NuggMD's video telehealth platform connects state-licensed medical marijuana doctors to their patients for affordable, safe online evaluations

NuggMD, the nation's leading medical marijuana telemedicine platform, is launching its service in Michigan for just $99 per evaluation for a limited time. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians in California, Connecticut, Illinois, Iowa, Maine, Maryland, Massachusetts, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, and Virginia.

In November 2019, just before recreational sales began, Michigan had 268,566 medical marijuana patients and 36,392 caregivers. By June 2021, nearly a year and a half later, the state still had 252,330 and 30,670. This small dip sharply contrasts with other states, which saw the number of registered patients plummet shortly after legalization.

"Having a medical marijuana card is still a huge advantage for patients in Michigan," says Alex Milligan, NuggMD Co-founder and CMO.

"You can assign a caregiver for cultivation, avoid the 10% excise tax, get extra discounts, access cannabis in cities that ban recreational sales, and even receive legal protections in medical-only states that offer reciprocity when traveling. It's easy to see why the medical marijuana market in Michigan is still strong."

Michigan's recreational cannabis laws allow anyone over 21 to cultivate up to 12 plants, but rental agencies and landlords can still restrict cultivation on their properties and often do. Patients in this situation who need commercially unpopular strains, or need to grow their own for other reasons can assign a caregiver to cultivate for them, often for much lower costs than dispensaries. Last year, the state legislature attempted to restrict caregiver cultivation amounts, but resistance from activist patients and caregivers derailed the restrictive legislation.

e-mail icon
Continue reading

Cannabis is indeed the best natural treatment for Parkinson’s disease, new studies show

PD patients have a high interest in treatment with medicinal cannabis, but lack knowledge about how to take it and especially the differences between THC and CBD.

Parkinson’s disease is one of the most common neurodegenerative disorders. It was named by Jean-Martin Charcot, a French neurologist, back in 1872 after the disease was first identified by James Parkinson in 1817. Over a century later, there is still no known cure for this disease which robs people of their dignity and quality of life. However, there have been numerous modern treatments that have been developed including dopamine therapy, surgery, and even deep brain stimulation for healing the affected area in the brain.

The problem with pharmaceutical medications which have been designed for Parkinson’s disease is that they also leave patients with numerous unwanted side effects. These drugs are primarily intended to increase dopamine levels since the symptoms of Parkinson’s occur when dopamine levels drop too low. While all Parkinson’s patients experience different symptoms, the common medications used are all the same; these include Levodopa, dopamine agonists, anticholinergics, glutamate antagonist, COMT inhibitors, and MAO-B inhibitors.

The side effects from Parkinson’s medications include nausea, low blood pressure, involuntary movements, hallucinations, confusion, and behavioral issues – such as the uncontrollable need to have sex or gamble.

Thankfully, more patients are finding hope using cannabis-based medications.

What the studies say

In 2021, a survey sent amongst patients with Parkinson’s disease in Germany analyzed the impact of cannabis products. The results, which were published in the Journal of Parkinson’s Disease, reported that more than half of the patients acknowledge positive clinical results.  In Germany, THC products can already prescribed for cases where conventional medications did not work. Meanwhile, CBD can be obtained without a prescription from the internet as well as pharmacies.

e-mail icon
Continue reading

The only way eating healthy and working out will help you live longer

No, you can’t make up for your bad eating habits just by working out. Here’s what a new study says will actually work.

New research highlights a sad reality — no matter how much you work out or how healthy you eat, a longer life will only occur if you do both of these things together.

The large study was published in the British Journal of Sports Medicine and counters the popular belief that working out eliminates some of the risks of eating an unhealthy diet or that eating healthy things counteracts staying in bed all day.

Researchers had a lot of data at their disposal, allowing them to publish a study that was thorough and that shed some light on a lot of issues. The data belonged to UK Biobank and came from over 350,000 people with a median age of 57, who filled out questionnaires about their diets and habits. At the start of the study, participants were healthy.

The study made some expected discoveries, like learning that participants who eat healthily and work out often had a lower mortality risk. Still, results highlighted that a healthy diet and frequent exercise were important independently.

“Physical activity is important. And whatever your physical activity is, diet is important,” said Dr. Melody Ding, lead author of the study.

Medical Cannabis Combats Anorexia's Obsessive Thoughts
Continue reading

SciSparc to submit IND for phase 2b trial of cannabis-derived therapy in Tourette syndrome

The new phase 2b trial expands on successful phase 2a findings, in which treatment with SCI-110 resulted in a 21% reduction in tics across a cohort of adults with Tourette syndrome.

SciSparc, a pharmaceutical company in development of central nervous system therapies, has begun the process of submitting an investigational new drug application (IND) for a phase 2b trial to evaluate their cannabis-derived agent SCI-110 in patients with Tourette Syndrome (TS). As part of the submission, the company is looking to expand the trial and include a site in the US.

The newly announced phase 2b trial stems from results of a previously conducted phase 2a trial, which showed that treatment using SCI-110 led to a 21% reduction of tic symptoms across a sample of patients with medically refractory TS. Additionally, the agent was proven to be safe, with no concerning AEs, and improved patients’ tic symptoms over time on the Yale Global Tic Severity Scale.

The news stems weeks after the company announced that it successfully completed the development of the formulation to be used in the multinational phase 2b study,2 along with news from January 2022 that they entered agreements to test the drug at 2 clinical trial sites in Hannover, Germany, and Tel-Aviv, Israel.3 SCI-110, currently in development for other indications, such as obstructive sleep apnea and Alzheimer disease (AD) agitation, contains a combination of dronabinol, an FDA-approved synthetic form of tetrahydrocannabinol (THC), with endocannabinoid palmitoylethanolamide (PEA).

The new multinational, double-blind, placebo-controlled crossover trial will evaluate the safety, efficacy, and tolerability of the agent in a cohort of adults aged 18 to 65 years with TS. Patients will be randomly assigned 1:1 to either study drug or placebo and evaluated on tic severity change at end points of week 12 and week 26 using commonly frequented measures. Additionally, the primary safety objective of the trial will be to assess absolute and relative frequencies of serious adverse events (AEs) for the entire population and separately for the SCI-110 and placebo groups.

"We are very excited about expanding our clinical sites to the US, especially after positive results obtained in a clinical trial led by professor Bloch MD, MS, an associate Professor in the Child Trial Center at Yale University, using our proprietary drug candidate," Adi Zuloff-Shani, chief technologies officer, SciSparc, said in a statement.

e-mail icon
Continue reading

WeedLife.com